Table 3.

Adverse events reported during the follow-up period.

Adverse event	Treatment group (n = 271)	Control group (n = 272)	P
Abnormal CBC	51 (18.8)	37 (13.6)	0.111
Abnormal kidney function	0 (0.0)	6 (2.2)	0.028
Abnormal stool analysis	7 (2.6)	2 (0.7)	0.156
Abnormal urine test	47 (17.3)	31 (11.4)	0.069
Abnormal ECG	3 (1.1)	4 (1.5)	0.643
Diarrhea	19 (7.0)	23 (8.5)	0.630
Gingival bleeding	22 (8.1)	32 (11.8)	0.197
Fatigue	28 (10.3)	26 (9.6)	0.776
Fever	6 (2.2)	8 (3.7)	0.448
Abdominal pain	42 (15.5)	59 (21.7)	0.077
Any other complaints	3 (1.2)	8 (3.0)	0.216

CBC, complete blood count; ECG, electrocardiogram. Other complaints included injury, extrauterine pregnancy, and intracranial tumor.